Bristol, Sanofi seek permanent block of Plavix generic

01/18/2007 | Bloomberg

Bristol-Myers Squibb and Sanofi-Aventis plan to move in court to block resumed marketing of a generic version of their Plavix blood thinner, in a trial set to begin Monday. The suit over generics maker Apotex's challenge to the Plavix patent is seen as critical to Bristol-Myers because the drug is its best-seller. A judge ordered Apotex to quit marketing its version last August.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN